Mirae Asset TIGER China Consumer ETF (150460)

Overview

NIOX Group Plc is a globally recognized entity in the realm of medical device innovation, primarily focusing on the development and commercialization of diagnostic equipment for measuring fractional exhaled nitric oxide (FeNO), a significant biomarker for asthma. Formerly known as Circassia Group Plc, the company underwent a rebranding in September 2022 to NIOX Group Plc, marking a new chapter in its commitment to advancing respiratory diagnosis. Since its inception in 2006, NIOX Group has established its operational headquarters in Oxford, the United Kingdom, cementing its position as a leader in the field of non-invasive asthma monitoring solutions. Their dedication to improving patient outcomes through innovative diagnostic tools has significantly impacted the way healthcare providers across the globe approach asthma management and treatment.

Products and Services

• NIOX VERO

The NIOX VERO stands as the flagship offering of NIOX Group Plc, embodying the pinnacle of non-invasive, point-of-care diagnostic systems designed for the precise measurement of FeNO levels in patients. This compact, portable device is accompanied by an assortment of critical consumables, ensuring its operational integrity and the reliability of test results. Among these consumables are sensors that accurately detect FeNO levels, individual disposable mouthpieces that guarantee patient safety and hygiene, and specialized breathing handles that facilitate ease of use for both healthcare providers and patients. The integration of these elements into the NIOX VERO system revolutionizes the approach to asthma diagnosis and monitoring, enabling more tailored and effective treatment plans.